| Year |
Citation |
Score |
| 2022 |
Chou YT, Bivona TG. Inhibition of SHP2 as an approach to block RAS-driven cancers. Advances in Cancer Research. 153: 205-236. PMID 35101231 DOI: 10.1016/bs.acr.2021.07.002 |
0.37 |
|
| 2021 |
Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, ... ... Bivona TG, et al. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell. PMID 33848463 DOI: 10.1016/j.cell.2021.03.031 |
0.467 |
|
| 2021 |
Kerr DL, Haderk F, Bivona TG. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current Opinion in Chemical Biology. 62: 1-12. PMID 33418513 DOI: 10.1016/j.cbpa.2020.11.007 |
0.342 |
|
| 2020 |
Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, ... ... Bivona TG, et al. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. PMID 32822576 DOI: 10.1016/J.Cell.2020.07.017 |
0.334 |
|
| 2020 |
Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, ... ... Bivona TG, et al. Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32540409 DOI: 10.1016/J.Jtho.2020.05.021 |
0.309 |
|
| 2020 |
Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, et al. AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug resistant cancer cells. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32018052 DOI: 10.1016/J.Jtho.2020.01.015 |
0.362 |
|
| 2020 |
Wu W, Okimoto RA, Blakely CM, Fraser J, Bivona TG. Targeted DNA sequencing analysis to reveal genetic diversity and androgen-receptor alteration in advanced EGFR mutant lung adenocarcinoma. Journal of Clinical Oncology. 38: 9526-9526. DOI: 10.1200/Jco.2020.38.15_Suppl.9526 |
0.308 |
|
| 2020 |
Haderk F, Allegakoen D, Guan J, Wu W, Bivona T. Abstract PR11: Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-Pr11 |
0.355 |
|
| 2020 |
Zaman A, Bivona T. Abstract B36: Therapy-induced YAP hyperactivation is a mechanism driving the evolution of residual disease and resistance to targeted cancer therapy Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-B36 |
0.391 |
|
| 2020 |
Haderk F, Fernández-Méndez C, Shah K, Wu W, Guan J, Rotow J, Allegakoen D, Olivas V, Bandyopadhyay S, Kuo C, Bivona T. B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC Journal of Thoracic Oncology. 15: S27. DOI: 10.1016/J.Jtho.2019.12.070 |
0.313 |
|
| 2019 |
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, ... ... Bivona TG, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548343 DOI: 10.1158/1078-0432.Ccr-19-1667 |
0.427 |
|
| 2019 |
Bracht JWP, Karachaliou N, Bivona T, Lanman RB, Faull I, Nagy RJ, Drozdowskyj A, Berenguer J, Fernandez-Bruno M, Molina-Vila MA, Rosell R. Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers. 11. PMID 31533235 DOI: 10.3390/Cancers11091381 |
0.377 |
|
| 2019 |
Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, ... ... Bivona TG, et al. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Reports. 28: 2317-2330.e8. PMID 31461649 DOI: 10.1016/J.Celrep.2019.07.063 |
0.352 |
|
| 2019 |
Zaman A, Wu W, Bivona TG. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers. 11. PMID 31426419 DOI: 10.3390/Cancers11081197 |
0.336 |
|
| 2019 |
Bivona TG. Dampening oncogenic RAS signaling. Science (New York, N.Y.). 363: 1280-1281. PMID 30898918 DOI: 10.1126/Science.Aav6703 |
0.51 |
|
| 2019 |
Halliday PR, Blakely CM, Bivona TG. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports. 21: 21. PMID 30806814 DOI: 10.1007/S11912-019-0770-X |
0.327 |
|
| 2019 |
Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in Molecular Medicine. PMID 30686761 DOI: 10.1016/J.Molmed.2018.12.009 |
0.312 |
|
| 2019 |
Negrao MV, Raymond VM, Lanman RB, Ng PKS, Nagy R, Banks K, Zhu VW, Amador BE, Roarty E, Chae YK, Clarke JM, Crawford J, Ou SI, Gandara DR, Heymach J, ... Bivona TG, et al. Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC. Journal of Clinical Oncology. 37: 3102-3102. DOI: 10.1200/Jco.2019.37.15_Suppl.3102 |
0.337 |
|
| 2019 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Kuhn J, Dumont S, Mccormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC Cancer Research. 79: 2902-2902. DOI: 10.1158/1538-7445.Am2019-2902 |
0.368 |
|
| 2019 |
Rotow J, Urisman A, Mccoach C, Jahan T, Bivona T, Jones K, Gupta A, Do H, Riess J, Aisner D, Doebele R, Jablons D, Kratz J, Blakely C. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1209 |
0.302 |
|
| 2018 |
Nanjo S, Bivona TG. Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Journal of Thoracic Disease. 10: S4061-S4064. PMID 30631555 DOI: 10.21037/Jtd.2018.09.106 |
0.331 |
|
| 2018 |
Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, ... Bivona TG, et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Research. PMID 30538120 DOI: 10.1158/0008-5472.Can-18-1492 |
0.378 |
|
| 2018 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, ... ... Bivona TG, et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature Medicine. PMID 30478424 DOI: 10.1038/S41591-018-0264-7 |
0.353 |
|
| 2018 |
Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway. Science (New York, N.Y.). 361. PMID 30166458 DOI: 10.1126/Science.Aao3048 |
0.494 |
|
| 2018 |
Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. Compensation of select proteostasis networks after Hsp70 inhibition in cancer. Journal of Cell Science. PMID 30131440 DOI: 10.1242/Jcs.217760 |
0.32 |
|
| 2018 |
Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, ... ... Bivona TG, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology. PMID 30104724 DOI: 10.1038/S41556-018-0169-1 |
0.55 |
|
| 2018 |
Zaman A, Bivona TG. Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Annals of Translational Medicine. 6: 160. PMID 29911108 DOI: 10.21037/Atm.2018.05.02 |
0.372 |
|
| 2018 |
Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, et al. IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29885479 DOI: 10.1016/J.Jtho.2018.05.030 |
0.325 |
|
| 2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Bivona TG, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035 |
0.406 |
|
| 2018 |
Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, ... ... Bivona TG, et al. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. Ebiomedicine. PMID 29433983 DOI: 10.1016/J.Ebiom.2018.02.001 |
0.356 |
|
| 2018 |
Karachaliou N, Chaib I, Cardona Zorrilla AF, Berenguer J, Bracht J, Yang J, Cai X, Wang Z, Drozdowskyj A, Attili I, Rodríguez JK, Rojas Puentes LL, Viteri Ramirez S, Ou SI, Mok T, ... Bivona TG, et al. AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC. Journal of Clinical Oncology. 36: e24003-e24003. DOI: 10.1200/Jco.2018.36.15_Suppl.E24003 |
0.325 |
|
| 2018 |
Rotow J, Wu W, Blakely CM, Lanman RB, Raymond VM, Kaye FJ, Gui P, Fraser J, Wolff A, Collisson EA, McCoach CE, Bivona TG. Concurrent genomic alterations in lung adenocarcinoma with a MET exon 14 skipping mutation. Journal of Clinical Oncology. 36: 9083-9083. DOI: 10.1200/Jco.2018.36.15_Suppl.9083 |
0.311 |
|
| 2018 |
Okimoto RA, Wu W, Bivona TG. Abstract B24: Molecular and functional dissection of the CIC-DUX4 fusion in undifferentiated round cell sarcoma Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-B24 |
0.316 |
|
| 2018 |
Bivona TG, Nichols R, Haderk F, Stahlhut C, Schulze C, Hemmati G, Wildes D. Abstract 3993: Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, NF1 loss and RAS-GTP-dependent oncogenic BRAF Cancer Research. 78: 3993-3993. DOI: 10.1158/1538-7445.Am2018-3993 |
0.537 |
|
| 2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, Dimitriadoy S, Liu DL, Kantheti HS, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, ... ... Bivona TG, et al. Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas Cancer Research. 78: 3302-3302. DOI: 10.1158/1538-7445.Am2018-3302 |
0.395 |
|
| 2018 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Hemmati GG, Krings G, Haringsma HJ, Simmons AD, Harding TC, Goga A, Blakely C, Bivona T, Bandyopadhyay S. Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer Cancer Research. 78: 1957-1957. DOI: 10.1158/1538-7445.Am2018-1957 |
0.377 |
|
| 2018 |
Shah K, Blakely C, Bivona T, Bandyopadhyay S. P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer Journal of Thoracic Oncology. 13: S585-S586. DOI: 10.1016/J.Jtho.2018.08.867 |
0.327 |
|
| 2018 |
Karachaliou N, Chaib I, Bracht J, Filipska M, Drozdowskyj A, Cardona A, Vergnenegre A, Sánchez-Torres J, Provencio M, De Marinis F, Carcereny E, Reguart N, García Campelo R, Santarpia M, Viteri S, ... Bivona T, et al. P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC Journal of Thoracic Oncology. 13: S721-S722. DOI: 10.1016/J.Jtho.2018.08.1202 |
0.306 |
|
| 2017 |
Bivona TG. Dividing and conquering the variation among variants in lung cancer. Translational Cancer Research. 6: S369-S370. PMID 30613480 DOI: 10.21037/Tcr.2017.03.25 |
0.346 |
|
| 2017 |
Wu W, Haderk F, Bivona TG. Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. Cancers. 9. PMID 29189709 DOI: 10.3390/Cancers9120164 |
0.346 |
|
| 2017 |
Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, ... ... Bivona TG, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics. PMID 29106415 DOI: 10.1038/Ng.3990 |
0.363 |
|
| 2017 |
Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews. Cancer. 17: 637-658. PMID 29068003 DOI: 10.1038/Nrc.2017.84 |
0.36 |
|
| 2017 |
Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nature Communications. 8: 823. PMID 29018192 DOI: 10.1038/S41467-017-00963-0 |
0.315 |
|
| 2017 |
Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, ... ... Bivona TG, et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications. 8: 410. PMID 28871105 DOI: 10.1038/S41467-017-00450-6 |
0.364 |
|
| 2017 |
Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clinical Pharmacology and Therapeutics. PMID 28786099 DOI: 10.1002/Cpt.810 |
0.309 |
|
| 2017 |
Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget. PMID 28521301 DOI: 10.18632/Oncotarget.17625 |
0.388 |
|
| 2017 |
Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, ... ... Bivona TG, et al. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute. 109. PMID 28376152 DOI: 10.1093/Jnci/Djx014 |
0.392 |
|
| 2017 |
Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports. 7: 44206. PMID 28287179 DOI: 10.1038/Srep44206 |
0.302 |
|
| 2017 |
Kyung Rho J, Young Lee I, Jung Choi Y, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, ... ... Bivona TG, et al. Superior efficacy and selectivity of novel small molecule kinase inhibitors of T790M mutant EGFR in preclinical models of lung cancer. Cancer Research. PMID 28082405 DOI: 10.1158/0008-5472.Can-16-2432 |
0.33 |
|
| 2017 |
Blakely CM, Wu W, Gubens MA, Rotow J, Wang V, Banks K, Lanman RB, Mack PC, Husain H, McCoach CE, Doebele RC, Riess J, Bivona TG. Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients. Journal of Clinical Oncology. 35: 9009-9009. DOI: 10.1200/Jco.2017.35.15_Suppl.9009 |
0.357 |
|
| 2017 |
Mayekar MK, Lin L, Bivona TG. Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition Cancer Research. 78: 920-920. DOI: 10.1158/1538-7445.Am2018-920 |
0.569 |
|
| 2017 |
Hedberg ML, Peyser N, Gooding W, Li H, Brand T, Olivas V, Bivona T, Choisea S, Wang L, Johnson J, Duvvuri U, Ferris R, Johnson D, Ha P, Bauman J, et al. Abstract 1779: Chronic NSAID use increases survival inPIK3CA-altered head and neck squamous cell carcinoma Cancer Research. 77: 1779-1779. DOI: 10.1158/1538-7445.Am2017-1779 |
0.312 |
|
| 2017 |
Ikeda S, Gay L, Pavlick D, Chung J, Ramkissoon S, Daniel S, Elvin J, Severson E, Bivona T, Reckamp K, Klempner S, Ou S, Schrock A, Miller V, Stephens P, et al. Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types Annals of Oncology. 28: x1. DOI: 10.1093/Annonc/Mdx652 |
0.308 |
|
| 2017 |
Rosell R, Karachaliou N, Chaib I, Drozdowskyj A, Frías A, Teixidó C, Viteri S, Santarpia L, Molina-Vila M, Bivona T. Innate resistance in EGFR mutant non-small cell lung cancer (NSCLC) patients by coactivation of receptor tyrosine kinases (RTKs) Annals of Oncology. 28: ii1. DOI: 10.1093/Annonc/Mdx090.003 |
0.348 |
|
| 2017 |
Raymond V, Bivona T, Lanman R, Nagy R, Banks K, Chae Y, Clarke J, Crawford J, Gandara D, Heymach J. OA 12.05 Spectrum of 1,014 Somatic BRAF Alterations Detected in Cell-Free DNA of Patients with Advanced Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 12: S1777-S1778. DOI: 10.1016/J.Jtho.2017.09.397 |
0.324 |
|
| 2017 |
Rosell R, Chaib I, Karachaliou N, Cao P, Molina Vila MA, Cai X, Drozdowskyj A, Yang J, Hu C, Cardona A, Frías A, Lazzari C, Verlicchi A, Codony Servat J, Codony Servat C, ... ... Bivona T, et al. OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer Journal of Thoracic Oncology. 12: S281-S282. DOI: 10.1016/J.Jtho.2016.11.284 |
0.332 |
|
| 2017 |
Karachaliou N, Chaib I, Cardona A, López-Vivanco G, Vergnenegre A, Sánchez JM, Provencio M, De Marinis F, Passaro A, Carcereny E, Reguart N, Campelo RG, Santarpia M, Viteri S, Molina Vila MA, ... ... Bivona T, et al. P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer Journal of Thoracic Oncology. 12: S1216-S1217. DOI: 10.1016/J.Jtho.2016.11.1714 |
0.359 |
|
| 2016 |
Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming. Oncotarget. PMID 27852038 DOI: 10.18632/Oncotarget.13307 |
0.346 |
|
| 2016 |
Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 27834212 DOI: 10.1073/Pnas.1610456113 |
0.438 |
|
| 2016 |
Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 27450084 DOI: 10.1073/Pnas.1603883113 |
0.33 |
|
| 2016 |
McCoach CE, Bivona TG, Blakely CM, Doebele RC. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer. PMID 27378174 DOI: 10.1016/J.Cllc.2016.05.025 |
0.387 |
|
| 2016 |
Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, ... Bivona TG, et al. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters. PMID 27343980 DOI: 10.1016/J.Canlet.2016.06.017 |
0.336 |
|
| 2016 |
Hrustanovic G, Bivona TG. RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Molecular & Cellular Oncology. 3: e1091061. PMID 27308613 DOI: 10.1080/23723556.2015.1091061 |
0.454 |
|
| 2016 |
Lin L, Bivona TG. The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors. Molecular & Cellular Oncology. 3: e1021441. PMID 27308535 DOI: 10.1080/23723556.2015.1021441 |
0.457 |
|
| 2016 |
Hrustanovic G, Bivona TG. RAS signaling in ALK fusion lung cancer. Small Gtpases. 7: 32-3. PMID 26901483 DOI: 10.1080/21541248.2015.1131803 |
0.489 |
|
| 2016 |
Okimoto RA, Bivona TG. Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discovery. 6: 14-6. PMID 26747892 DOI: 10.1158/2159-8290.Cd-15-1352 |
0.301 |
|
| 2016 |
Blakely CM, Banks KC, Lanman RB, Riess J, Mack PC, Bivona TG. Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma. Journal of Clinical Oncology. 34: e23079-e23079. DOI: 10.1200/Jco.2016.34.15_Suppl.E23079 |
0.346 |
|
| 2016 |
Karachaliou N, Chaib I, Pilotto S, Codony J, Cai X, Li X, Drozdowskyj A, Codony C, Cardona AF, López-Vivanco G, Vergnenègre A, Sánchez JM, Provencio M, Marinis Fd, Carcereny E, ... ... Bivona T, et al. Abstract 265: Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients Cancer Research. 76: 265-265. DOI: 10.1158/1538-7445.Am2016-265 |
0.376 |
|
| 2016 |
Karachaliou N, Chaib I, Cai X, Li X, Cardona A, López-Vivanco G, Vergnenegre A, Torres JS, Provencio M, de Marinis F, Carecereny E, Reguart N, Campelo RG, Viteri S, Vila MM, ... ... Bivona T, et al. Poly-therapy with EGFR, STAT3 and Src-YAP1 signaling pathway inhibition; A breakthrough for EGFR mutant NSCLC Annals of Oncology. 27: vi411. DOI: 10.1093/Annonc/Mdw382.02 |
0.341 |
|
| 2016 |
Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona TG. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation Oncogene. 35: 1198-1205. DOI: 10.1038/Onc.2015.173 |
0.431 |
|
| 2015 |
Okimoto RA, Bivona TG. AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckland, N.Z.). 6: 27-34. PMID 28210148 DOI: 10.2147/Lctt.S60438 |
0.348 |
|
| 2015 |
Hrustanovic G, Bivona TG. RAS-MAPK in ALK targeted therapy resistance. Cell Cycle (Georgetown, Tex.). 14: 3661-2. PMID 26654768 DOI: 10.1080/15384101.2015.1096103 |
0.455 |
|
| 2015 |
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, ... ... Bivona TG, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nature Medicine. 21: 1038-47. PMID 26301689 DOI: 10.1038/Nm.3930 |
0.429 |
|
| 2015 |
Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell Cycle (Georgetown, Tex.). 14: 1765-6. PMID 26036142 DOI: 10.1080/15384101.2015.1032644 |
0.301 |
|
| 2015 |
Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, ... ... Bivona TG, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 27: 533-46. PMID 25873175 DOI: 10.1016/J.Ccell.2015.03.010 |
0.379 |
|
| 2015 |
Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, ... ... Bivona TG, et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Reports. 11: 98-110. PMID 25843712 DOI: 10.1016/J.Celrep.2015.03.012 |
0.361 |
|
| 2015 |
Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. Plos One. 10: e0119832. PMID 25780909 DOI: 10.1371/Journal.Pone.0119832 |
0.34 |
|
| 2015 |
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, ... ... Bivona TG, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics. 47: 250-6. PMID 25665005 DOI: 10.1038/Ng.3218 |
0.431 |
|
| 2015 |
Sabnis AJ, Guerriero CJ, Brodsky JL, Bivona T. Abstract 481: Rationale for targeting the protein chaperone network in rhabdomyosarcoma Cancer Research. 75: 481-481. DOI: 10.1158/1538-7445.Am2015-481 |
0.338 |
|
| 2015 |
Westesson O, Nielsen R, John JS, Caulin A, Hahner N, Stewart S, Foo C, Lung K, Catalano J, Lee M, Giannikopoulos P, Polkinghorn W, Wiessman J, Regev A, Bivona T. Abstract 2173: Robust estimation of mutation burden Cancer Research. 75: 2173-2173. DOI: 10.1158/1538-7445.Am2015-2173 |
0.302 |
|
| 2015 |
Pazarentzos E, Bivona TG. Adaptive stress signaling in targeted cancer therapy resistance Oncogene. 34: 5599-5606. DOI: 10.1038/Onc.2015.26 |
0.316 |
|
| 2015 |
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, ... ... Bivona TG, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer Nature Medicine. DOI: 10.1038/nm.3930 |
0.378 |
|
| 2014 |
Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine. Personalized Medicine. 11: 309-321. PMID 25506379 DOI: 10.2217/Pme.14.19 |
0.321 |
|
| 2014 |
Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treatment Reviews. 40: 990-1004. PMID 24953979 DOI: 10.1016/J.Ctrv.2014.05.009 |
0.346 |
|
| 2014 |
Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: E748-57. PMID 24550319 DOI: 10.1073/Pnas.1320956111 |
0.402 |
|
| 2014 |
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, ... ... Bivona T, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2001-10. PMID 24493829 DOI: 10.1158/1078-0432.Ccr-13-2233 |
0.326 |
|
| 2014 |
Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Human Mutation. 35: 318-28. PMID 24323975 DOI: 10.1002/Humu.22493 |
0.33 |
|
| 2014 |
Ma PC, Thiagarajan P, Leahy P, Bagai RK, Shi I, Zhang W, Feng Y, Veigl ML, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG. Adaptive cell plasticity in autocrine TGFβ2 coordinated transcriptome-metabolome reprogramming of EGFR-mutant lung cancer in precision therapy escape. Journal of Clinical Oncology. 32: e19043-e19043. DOI: 10.1200/Jco.2014.32.15_Suppl.E19043 |
0.337 |
|
| 2014 |
Giannikopoulos P, St. John JA, Parker JS, Westesson O, Hahner NJ, Karachaliou N, Costa C, Caulin AF, Lozano MD, Perez-Gracia JL, Curioni Fontecedro A, Jantus-Lewintre E, Vergnenegre A, Gervais R, Bordoni R, ... ... Bivona TG, et al. Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers. Journal of Clinical Oncology. 32: 8083-8083. DOI: 10.1200/Jco.2014.32.15_Suppl.8083 |
0.362 |
|
| 2014 |
Giannikopoulos P, John JS, Hahner N, Parker JS, Karachaliou N, Costa C, Westesson O, Parikh U, Foo CK, Cauhlin AF, Lozano MD, Viteri S, Perez-Gracia JL, Curioni A, Jantus-Lewintre E, ... ... Bivona TG, et al. Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib Cancer Research. 74: 954-954. DOI: 10.1158/1538-7445.Am2014-954 |
0.365 |
|
| 2014 |
Foo CK, John JS, Hahner N, Westesson O, Skinner ME, Parikh U, Lung K, Cauhlin AF, Catalano JP, Wellde AS, Barry JK, Wellde GW, Ma P, Rosell R, Zorilla AFC, ... ... Bivona TG, et al. Abstract 4707: Comprehensive integrated genomic analysis Cancer Research. 74: 4707-4707. DOI: 10.1158/1538-7445.Am2014-4707 |
0.308 |
|
| 2014 |
Blakely CM, Pazarentzos E, Asthana S, Olivas V, Tan I, Fouts T, Meshulam J, Bivona TG. Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma Cancer Research. 74: 1836-1836. DOI: 10.1158/1538-7445.Am2014-1836 |
0.369 |
|
| 2014 |
Pazarentzos E, Bivona TG. Abstract 1713: PDK1 and hexokinase 2 are downstream effectors of PTEN loss and regulate response to targeted therapies in multiple tumor types Cancer Research. 74: 1713-1713. DOI: 10.1158/1538-7445.Am2014-1713 |
0.365 |
|
| 2013 |
Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet (London, England). 382: 720-31. PMID 23972815 DOI: 10.1016/S0140-6736(13)61715-8 |
0.38 |
|
| 2013 |
Sabnis AJ, Bivona TG. FGFR fusions in the driver's seat. Cancer Discovery. 3: 607-9. PMID 23749526 DOI: 10.1158/2159-8290.Cd-13-0185 |
0.305 |
|
| 2013 |
Hrustanovic G, Lee BJ, Bivona TG. Mechanisms of resistance to EGFR targeted therapies. Cancer Biology & Therapy. 14: 304-14. PMID 23358468 DOI: 10.4161/Cbt.23627 |
0.327 |
|
| 2013 |
Bivona TG, Giannikopoulos P, Costa C, Karachaliou N, Viteri S, Garcia-Campelo MR, John JS, Uzilov AV, Wellde AS, Polkinghorn WR, Majem M, Felip E, Carcereny E, Heidecke CN, Massuti B, et al. Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients. Journal of Clinical Oncology. 31: 11067-11067. DOI: 10.1200/Jco.2013.31.15_Suppl.11067 |
0.326 |
|
| 2013 |
Karachaliou N, Drozdowskyj A, Costa C, Molina-Vila MA, Capitan AG, Vergnenegre A, Massuti B, Moran T, Majem M, Felip E, Costa EC, Garcia-Campelo MR, Ramirez SV, Heidecke CN, Estrada-Tejedor R, ... ... Bivona TG, et al. ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target. Journal of Clinical Oncology. 31: 11027-11027. DOI: 10.1200/Jco.2013.31.15_Suppl.11027 |
0.352 |
|
| 2013 |
Weissman JS, Giannikopoulos P, John JS, Uzilov AV, Costa C, Karachaliou N, Sansano I, Jantus-Lewintre E, Stahel RA, Vergnenegre A, Gervais R, Perez-Gracia JL, Lozano MD, Wellde AS, Bordoni R, ... ... Bivona TG, et al. Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib. Journal of Clinical Oncology. 31: 11010-11010. DOI: 10.1200/Jco.2013.31.15_Suppl.11010 |
0.338 |
|
| 2013 |
Blakely CM, Lin L, Asthana S, Sidiropoulos N, Nelson T, Bastian BC, Gubens MA, Taylor BS, Bivona TG. Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling. Journal of Clinical Oncology. 31: 11004-11004. DOI: 10.1200/Jco.2013.31.15_Suppl.11004 |
0.354 |
|
| 2013 |
Blakely CM, Olivas V, Zhang J, Bivona TG. Abstract 4631: Pharmacologic inhibition of NF-kappaB overcomes de novo resistance to erlotinib in models of EGFR-mutant lung adenocarcinoma. Cancer Research. 73: 4631-4631. DOI: 10.1158/1538-7445.Am2013-4631 |
0.389 |
|
| 2012 |
Blakely CM, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discovery. 2: 872-5. PMID 23071030 DOI: 10.1158/2159-8290.Cd-12-0387 |
0.339 |
|
| 2012 |
Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemotherapy Research and Practice. 2012: 817297. PMID 22970367 DOI: 10.1155/2012/817297 |
0.336 |
|
| 2012 |
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, ... ... Bivona TG, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics. 44: 852-60. PMID 22751098 DOI: 10.1038/Ng.2330 |
0.369 |
|
| 2011 |
Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 108: 19024-9. PMID 22065749 DOI: 10.1073/Pnas.1111963108 |
0.398 |
|
| 2011 |
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 471: 523-6. PMID 21430781 DOI: 10.1038/Nature09870 |
0.37 |
|
| 2011 |
Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, ... ... Bivona TG, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1160-8. PMID 21233402 DOI: 10.1158/1078-0432.Ccr-10-2158 |
0.329 |
|
| 2008 |
Quatela SE, Sung PJ, Ahearn IM, Bivona TG, Philips MR. Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis. Methods in Enzymology. 439: 87-102. PMID 18374158 DOI: 10.1016/S0076-6879(07)00407-7 |
0.78 |
|
| 2006 |
Bivona TG, Quatela S, Philips MR. Analysis of Ras activation in living cells with GFP-RBD. Methods in Enzymology. 407: 128-43. PMID 16757320 DOI: 10.1016/S0076-6879(05)07012-6 |
0.801 |
|
| 2006 |
Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Pérez de Castro I, Li C, Thompson CB, et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Molecular Cell. 21: 481-93. PMID 16483930 DOI: 10.1016/J.Molcel.2006.01.012 |
0.73 |
|
| 2005 |
Bivona TG, Philips MR. Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains. Methods (San Diego, Calif.). 37: 138-45. PMID 16289969 DOI: 10.1016/J.Ymeth.2005.05.022 |
0.734 |
|
| 2005 |
Jordan JD, He JC, Eungdamrong NJ, Gomes I, Ali W, Nguyen T, Bivona TG, Philips MR, Devi LA, Iyengar R. Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. The Journal of Biological Chemistry. 280: 11413-21. PMID 15657046 DOI: 10.1074/Jbc.M411521200 |
0.539 |
|
| 2004 |
Perez de Castro I, Bivona TG, Philips MR, Pellicer A. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Molecular and Cellular Biology. 24: 3485-96. PMID 15060167 DOI: 10.1128/Mcb.24.8.3485-3496.2004 |
0.722 |
|
| 2004 |
Walker SA, Kupzig S, Bouyoucef D, Davies LC, Tsuboi T, Bivona TG, Cozier GE, Lockyer PJ, Buckler A, Rutter GA, Allen MJ, Philips MR, Cullen PJ. Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations. The Embo Journal. 23: 1749-60. PMID 15057271 DOI: 10.1038/Sj.Emboj.7600197 |
0.641 |
|
| 2004 |
Dustin ML, Bivona TG, Philips MR. Membranes as messengers in T cell adhesion signaling. Nature Immunology. 5: 363-72. PMID 15052266 DOI: 10.1038/Ni1057 |
0.597 |
|
| 2004 |
Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Molecular Cell. 13: 341-55. PMID 14967142 DOI: 10.1016/S1097-2765(04)00050-4 |
0.686 |
|
| 2004 |
Bivona TG, Wiener HH, Ahearn IM, Silletti J, Chiu VK, Philips MR. Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion. The Journal of Cell Biology. 164: 461-70. PMID 14757755 DOI: 10.1083/Jcb.200311093 |
0.755 |
|
| 2003 |
Mohney RP, Das M, Bivona TG, Hanes R, Adams AG, Philips MR, O'Bryan JP. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. The Journal of Biological Chemistry. 278: 47038-45. PMID 12970366 DOI: 10.1074/Jbc.M303895200 |
0.72 |
|
| 2003 |
Bivona TG, Pérez De Castro I, Ahearn IM, Grana TM, Chiu VK, Lockyer PJ, Cullen PJ, Pellicer A, Cox AD, Philips MR. Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature. 424: 694-8. PMID 12845332 DOI: 10.1038/Nature01806 |
0.817 |
|
| 2003 |
Bivona TG, Philips MR. Ras pathway signaling on endomembranes. Current Opinion in Cell Biology. 15: 136-42. PMID 12648668 DOI: 10.1016/S0955-0674(03)00016-4 |
0.71 |
|
| 2002 |
Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, Philips MR. Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biology. 4: 343-50. PMID 11988737 DOI: 10.1038/Ncb783 |
0.795 |
|
| Show low-probability matches. |